CNS Pipeline Fact Book 2012
Essential facts, figures and listings on the drugs, development phase, indication and approaches for 275 products from 127 companies
February 15th 2012
70
£445 / $690 / €530
Online, PDF
The affordable desk reference for easily reviewing the state of the global CNS drug development landscape
The CNS pipeline is second only to cancer in terms of the number of pharmaceuticals in development. Espicom has looked at Phases I, II and III of the clinical development programme and has identified more than 270 agents. These include new chemical entities and biologicals, as well as novel formulations of known drugs and new indications for approved drugs in lifecycle development. While many more are in preclinical development, this report focuses on pharmaceuticals that have progressed to clinical studies in humans.
With this report you can instantly...
- Know what drugs for Alzheimer’s disease are in Phase II
- Assess the CNS research portfolio for leading and emerging companies
- Identify your research competitors and possible collaborators
- Focus on companies who are targeting Multiple Sclerosis, and their status
- Review drugs by specific routes of administration
Delivered to all customers in the brilliant new Espicom Interactive!
While you can choose print or pdf, you will get – at no extra charge – access in Espicom Interactive, an advanced search and display interface. Make your investment in this report really pay, with valuable and practical user benefits, including:
- Fast full-text search results
- “One click” export of graphs/tables to MS PowerPoint and MS Excel
- 9 language machine translations
- “Build your own report” facility
